Key facts
- Zenitar Biomedical’s last known valuation is $479.0M (Nov 2025).
- It has raised $165.1M; the latest was IPO in Jan 2026.
- Notable investors include Qiming Venture Partners, 5Y Capital, Lanchi Ventures, Tencent Investment, Orinno Capital — 27 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Zenitar Biomedical
- ·The full record, as it builds
Funding rounds
No funding rounds for Zenitar Biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zenitar Biomedical
Developer of innovative biopharmaceutical technologies designed to accelerate the discovery and commercialization of new drugs. The company offers comprehensive drug R&D platform covering target research, molecule design, preclinical evaluation, and clinical development, supported by resources from the State Key Laboratory of Biotherapy and Guizhou Bailing Group, thereby helping healthcare providers and patients access advanced therapies, enabling breakthroughs in disease treatment and improved clinical outcomes.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2019
- Employees
- 71
- Website
- zenitar.com.cn/
- Ownership
- In IPO Registration
Zenitar Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zenitar Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zenitar Biomedical in its N-PORT filings yet. We sweep new filings monthly.